The Europe BNP and NT-proBNP Market would witness market growth of 10.7% CAGR during the forecast period (2022-2028).
Cardiovascular (CVD) diseases, the leading cause of complications and mortality, need a thorough multi-parameter evaluation beyond the ECG. BNP and NTproBNP assays are essential for early monitoring, detecting, and treating cardiac issues. This enables more advanced and efficient cardiac care. The main behavioral risk factors for CVD, including heart disease and stroke, entail inadequate or incorrect dietary intake, inactivity, tobacco use, and excessive alcohol consumption.
In addition, behavioral risk factors in humans might manifest as high blood pressure, increased blood sugar, high blood lipids, being overweight, and obesity. These risk factors can be evaluated in the context of primary care and demonstrate a higher risk of consequences like heart attack, heart failure, and stroke.
The underlying factors of CVDs also include other factors. They illustrate the three key factors—urbanization, population aging, and globalization—that are bringing about transformation in economic, social, and cultural respects. Other CVD predictors include hereditary variables, stress, and poverty. Pharmacological treatment for high blood pressure or hypertension, diabetes, and high blood lipids is also necessary to reduce cardiovascular risk and prevent strokes as well as heart attacks in people with these disorders.
Every year, 3.9 million individuals in Europe die from cardiovascular disease. 37% of all mortality in the EU is caused by CVD. Central and Eastern Europe has more fatalities from IHD (ischemic heart disease) and stroke than other parts of Europe. Over 49 million people in the EU and 85 million in Europe are estimated to have cardiovascular disease in 2015. Of all the behavioral risk factors, food and eating habits had the greatest impact on the likelihood of CVD (cardiovascular disease) mortality and CVD DALYs (CVD disability-adjusted life years) at the population level in Europe. Similarly, the potential medical risk with the greatest effect is high systolic blood pressure. The demand for bnp and ntprobnp, propagating the expansion of the regional market.
The Germany market dominated the Europe BNP and NT-proBNP Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $147.4 Million by 2028. The UK market is anticipated to grow at a CAGR of 9.9% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 11.6% during (2022 - 2028).
Based on Location of Testing, the market is segmented into Point of Care Testing and Laboratory Testing. Based on Application, the market is segmented into Myocardial Infarction, Acute Coronary Syndrome (ACS), Congestive Heart Failure (CHF) and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide BNP and NT-proBNP Market is Projected to reach USD 2.2 Billion by 2028, at a CAGR of 11.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Siemens AG, Danaher Corporation, Gentian Diagnostics ASA, PerkinElmer, Inc., BioMérieux S.A., Quidel Corporation, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd. (Roche Holding Ltd.), and Scripps Laboratories.
By Location of Testing
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
